中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 8
Aug.  2018
Turn off MathJax
Article Contents

Corticosteroid therapy for autoimmune pancreatitis

DOI: 10.3969/j.issn.1001-5256.2018.08.002
  • Received Date: 2018-04-20
  • Published Date: 2018-08-20
  • Autoimmune pancreatitis ( AIP) is a special type of autoimmune-mediated chronic pancreatitis and has unique imaging, serological, and histopathological features. According to current international guidelines, AIP is classified into type I and type II. Studies have shown that glucocorticoids have a good clinical effect in the treatment AIP, and the guidelines recommend oral glucocorticoids as the preferred treatment regimen for patients without contraindications. However, no consensus has been reached on initial dosage of glucocorticoids and treatment regimens after recurrence. Therefore, with reference to recent research advances and recommendations in guidelines, this article elaborates on the selection of treatment regimens for AIP from the aspects of the selection and treatment of previously untreated AIP patients and the treatment of patients with recurrence.

     

  • loading
  • [1]OKAZAKI K, KAWA S, KAMISAWA T, et al.Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013I.Concept and diagnosis of autoimmune pancreatitis[J].J Gastroenterol, 2014, 49 (4) :567-588.
    [2]CHARI ST, SMYRK TC, LEVY MJ, et al.Diagnosis of autoimmune pancreatitis:The Mayo Clinic experience[J].Clin Gastroenterol Hepatol, 2006, 4 (8) :1010-1016.
    [3] SHIMOSEGAWA T, CHARI ST, FRULLONI L, et al.International consensus diagnostic criteria for autoimmune pancreatitis:Guidelines of the International Association of Pancreatology[J].Pancreas, 2011, 40 (3) :352-358.
    [4] Editorial Board of Chinese Journal of Pancreatology.Chinese guidelines for the diagnosis and treatment of autoimmune pancreatitis (draft 2012, Shanghai) [J].Chin J Pancreatol, 2012, 12 (6) :410-418. (in Chinese) 《中华胰腺病杂志》编委会.我国自身免疫性胰腺炎共识意见 (草案2012, 上海) [J].中华胰腺病杂志, 2012, 12 (6) :410-418.
    [5]SUGUMAR A, CHARI ST.Diagnosis and treatment of autoimmune pancreatitis[J].Curr Opin Gastroenterol, 2010, 26 (5) :513-518.
    [6]KUBOTA K, IIDA H, FUJISAWA T, et al.Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis[J].Gastrointest Endosc, 2007, 66 (6) :1142-1151.
    [7]KAMISAWA T, OKAZAKI K, KAWA S, et al.Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013.III.Treatment and prognosis of autoimmune pancreatitis[J].J Gastroenterol, 2014, 49 (6) :961-970.
    [8]KHOSROSHAHI A, WALLACE ZS, CROWE JL, et al.International consensus guidance statement on the management and treatment of Ig G4-related disease[J].Arthritis Rheumatol, 2015, 67 (7) :1688-1699.
    [9] KAMISAWA T, SHIMOSEGAWA T, OKAZAKI K, et al.Standard steroid treatment for autoimmune pancreatitis[J].Gut, 2009, 58 (11) :1504-1507.
    [10]HART PA, ZEN Y, CHARI ST.Recent advances in autoimmune pancreatitis[J].Gastroenterology, 2015, 149 (1) :39-51.
    [11]ARAKI J, TSUJIMOTO F, OHTA T, et al.Natural course of autoimmune pancreatitis without steroid therapy showing hypoechoic masses in the uncinated process and tail of the pancreas on ultrasonography[J].J Ultrasound Med, 2006, 25 (8) :1063-1067.
    [12]ITO T, NISHIMORI I, INOUE N, et al.Treatment for autoimmune pancreatitis:Consensus on the treatment for patients with autoimmune pancreatitis in Japan[J].J Gastroenterol, 2007, 42 (Suppl18) :50-58.
    [13]KANNO A, MASAMUNE A, OKAZAKI K, et al.Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2011[J].Pancreas, 2015, 44 (4) :535-539.
    [14]BUIJS J, van HEERDE MJ, RAUWS EA, et al.Comparable efficacy of low-versus high-dose induction corticosteroid treatment in autoimmune pancreatitis[J].Pancreas, 2014, 43 (2) :261-267.
    [15]TOMIYAMA T, UCHIDA K, MATSUSHITA M, et al.Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis[J].J Gastroenterol, 2011, 46 (5) :696-704.
    [16]PARK DH, KIM MH, OH HB, et al.Substitution of aspartic acid at position 57 of the DQb1 affects relapse of autoimmune pancreatitis[J].Gastroenterology, 2008, 134 (2) :440-446.
    [17]HAN PA, KAMISAWA T, BNLGGE WR, et al.Long-term outcomes of autoimmune pancreatitis:A multicenter, international analysis[J].Gut, 2013, 62 (12) :1771-1776.
    [18]WAKABAYASHI T, KAWAURA Y, SATOMURA Y, et al.Longterm prognosis of duct-narrowing chronic pancreatitis:Strategy for steroid treatment[J].Pancreas, 2005, 30 (1) :31-39.
    [19]MASAMUNE A, NISHIMORI I, KIKUTA K, et al.Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis[J].Gut, 2017, 66 (3) :487-494.
    [20]GHAZALE A, CHARI ST, ZHANG L, et al.Immunoglobulin G4-associated cholangitis:Clinical profile and response to therapy[J].Gastroenterology, 2008, 134 (3) :706-715.
    [21]LIU B, LI J, YAN LN, et al.Retrospective study of steroid therapy for patients with autoimmune pancreatitis in a Chinese population[J].World J Gastroenterol, 2013, 19 (4) :569-574.
    [22]SAH RP, CHARI ST, PANNALA R, et al.Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis[J].Gastroenterology, 2010, 139 (1) :140-148.
    [23]HUGGETT MT, CULVER EL, KUMAR M, et al.Type 1 autoimmune pancreatitis and Ig G4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort[J].Am J Gastroenterol, 2014, 109 (10) :1675-1683.
    [24]KAMISAWA T, OKAMOTO A.Prognosis of autoimmune pancreatitis[J].J Gastroenterol, 2007, 42 (Suppl 18) :s59-s62.
    [25]KIM KP, KIM MH, SONG MH, et al.Autoimmune chronic pancreatitis[J].Am J Gastroenterol, 2004, 99 (8) :1605-1616.
    [26]LOPEZ-SERRANO A, CRESPO J, PASCUAL I, et al.Diagnosis, treatment and long-term outcomes of autoimmune pancreatitis in Spain based on the International Consensus Diagnostic Criteria:A multi-centre study[J].Pancreatology, 2016, 16 (3) :382-390.
    [27]SHIMIZU S, NAITOH I, NAKAZAWA T, et al.Correlation between long-term outcome and steroid therapy in type 1 autoimmune pancreatitis:Relapse, malignancy and side effect of steroid[J].Sca Ild J Gastroenterol, 2015, 50 (11) :1411-1418.
    [28]HIMNO K, TADA M, ISAYAMA H, et al.Outcome of long-term maintenance steroid therapy cessation in patients with autoimmune pancreatitis:A prospective study[J].J Clin Gastroenterol, 2016, 50 (4) :331-337.
    [29]RAINA A, YADAV D, KRASINSKAS AM, et al.Evaluation and management of autoimmune pancreatitis:Experience at a large US center[J].Am J Gastroenterol, 2009, 104 (9) :2295-2306.
    [30]MENG Q, XIN L, LIU W, et al.Diagnosis and treatment of autoimmune pancreatitis in China:A systematic review[J].PLo S One, 2015, 10 (6) :e0130466.
    [31]NISHINO T, TOKI F, OYAMA H, et al.Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy[J].Intem Med, 2006, 45 (8) :497-501.
    [32]MATSUSHITA M, YALLLASHINA M, IKEUM T, et al.Effective steroid pulse therapy for the biliary stenosis caused by autoimmune pancreatitis[J].Am J Gastroenterol, 2007, 102 (1) :220-221.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2226) PDF downloads(492) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return